

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

Review Proposal Project

NICE Technology Appraisal guidance no. 127; Natalizumab for the treatment of multiple sclerosis

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> • Biogen Idec and Elan Pharma International)(natalizumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Afiya Trust • Black Health Agency • Brain and Spine Foundation • Chinese National Healthy Living Centre • Connect • Counsel and Care • Equalities National Council • Leonard Cheshire Disability • Multiple Sclerosis National Therapy Centres • Multiple Sclerosis Resource Centre • Multiple Sclerosis Society • Multiple Sclerosis Trust • Muslim Council of Britain • Muslim Health Network • Neurological Alliance • Neurosupport • Royal Association for Disability and Rehabilitation (RADAR) • South Asian Health Foundation • Specialised Healthcare Alliance • Sue Ryder Care <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of British Neurologists 	<p><u>General</u></p> <ul style="list-style-type: none"> • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • NHS Alliance • NHS Commercial Medicines Unit • NHS Confederation • NHS Quality Improvement Scotland • Public Health Wales NHS Trust • Scottish Medicines Consortium <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> • Bayer (Interferon beta-1b) • Biogen Idec (Interferon beta-1a) • Merck Serono (Inteferon beta-1a) • Novartis Pharmaceuticals (Interferon beta-1b) • Sanofi Aventis (glatiramer acetate) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Neurological Research Trust • MRC Clinical Trials Unit • National Institute for Health Research

National Institute for Health and Clinical Excellence

NICE Technology Appraisal guidance no. 127; Natalizumab for the treatment of multiple sclerosis

Date: September 2010

APPENDIX A

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • British Association for Services to the Elderly • British Geriatrics Society • British Neuropathological Society • British Society of Rehabilitative Medicine • Chartered Society of Physiotherapy • Institute of Neurology • Primary Care Neurology Society • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Therapists in MS (TIMS) • United Kingdom Clinical Pharmacy Association • United Kingdom Multiple Sclerosis Specialist Nurse Association (UKMSSNA) <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • East and North Hertfordshire NHS Trust • NHS Bradford and Airedale • Welsh Assembly Government 	<ul style="list-style-type: none"> • Neurosciences Research Unit, University of Liverpool • Policy Research Institute on Ageing and Ethnicity • Research Institute for the Care of Older People <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> • National Institute for Health Research Health Technology Assessment <p><u>Associated Guideline Group</u></p> <ul style="list-style-type: none"> • National Clinical Guideline Centre <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • (none)

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

National Institute for Health and Clinical Excellence

NICE Technology Appraisal guidance no. 127; Natalizumab for the treatment of multiple sclerosis

Date: September 2010

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.